

Abstract LB-007 Table 1 Demographic and stroke characteristics of study patients (n=260)

Age, years, median (IQR)	69.5 (60 - 79)
ICA Occlusions	33 (12.7%)
MCA - M1 Occlusions	150 (57.7%)
MCA - M2 Occlusions	62 (23.8%)
Vertebral Occlusions	0 (0.0%)
Basilar Occlusions	11 (4.2%)
Multiple Territories	4 (1.5%)
Time from Symptom Onset to Groin Puncture, hours, median (IQR)	3 (2.4 - 4.3)
NIHSS score at admission, median (IQR)	15 (10 - 20)
Baseline ASPECTS, median (IQR)	8 (7 - 10)

numerically lower rate of rescue therapy than prior thrombectomy trials. Preliminary signal suggests super-large bore catheter positioning may influence the need for stent retrieval rescue therapy.

Disclosures W. Mack: 1; C; National Institutes of Health. 2; C; Imperative Care, Medtronic, Stryker, Viseon, Integra, Stream Biomedical, Egret Therapeutics, Spartan Micro. 4; C; Viseon, Q'Apel, Cerebrotech, Endostream, Stream Biomedical, Spartan Micro, Radical Catheters, Vastrax, Borvo, Egret Therapeutics. 5; C; University of Southern California. R. Nogueira: 2; C; Imperative Care. J. Grossberg: None. S. Majidi: 2; C; Imperative Care. D. Tomalty: None. M. Mokin: 2; C; Imperative Care. J. Vargas: 2; C; Imperative Care. B. Cucchiara: None. K. Snyder: None. J. Mascitelli: None. V. Parada: None. H. Shakir: 2; C; Imperative Care. D. Rosenbaum-HaLevi: None. N. Aghaebrahim: None. D. Hoit: 2; C; Imperative Care. B. Yim: 2; C; Imperative Care. M. Tenser: None. A. Al-Bayati: None. J. Milburn: 2; C; Imperative Care. J. Singer: None. S. Nimjee: None. N. Haranhalli: None. S. Sheth: None. D. Shaff: None. K. Layton: None. N. Beaty: None. R. Starke: None. H. Hawk: 2; C; Imperative Care. D. Haussen: None. A. Pabaney: None. C. Kellner: None. R. De Leacy: 2; C; Imperative Care.

LB-008 ENHANCING THROMBECTOMY OUTCOMES WITH ADAPTIVE PULSATILE ASPIRATION (APA™): THE ROLE OF COMPLETE CLOT INGESTION (CCI) IN REDUCING THROMBECTOMY TIME AND DISTAL EMBOLIZATION

¹R Starke*, ²J Thompson, ¹M Silva, ¹S Sanikommu, ¹A Abdelsalam, ¹J Toledo, ¹T Elarjani, ¹E Jaman. ¹Department of Neurosurgery, University of Miami, Miami, FL; ²University of Miami, Miami, FL

10.1136/jnis-2024-SNIS.407

Background Achieving radiographic reperfusion (TICI 3) in acute ischemic stroke thrombectomy may be an inadequate outcome measure. Unvisualized distal emboli even in the setting of TICI3 revascularization may lead to poor clinical outcomes. This study introduces a novel outcome metric, Complete Clot Ingestion (CCI). CCI is defined as full ingestion of the clot into the catheter or pump canister without any external clot remnants at the catheter tip. We hypothesizing that partially ingested ("corked") clots pose a higher risk of distal emboli.

Methods We evaluated two thrombectomy pump devices: the ALGO Smart Pump (Von Vascular, Inc, Sunrise, FL) and the Penumbra ENGINE Pump (Alameda, CA), focusing on their

efficacy in achieving CCI using medium-bore aspiration catheters. The ALGO Smart Pump works by a novel mechanism of Adaptive Pulsatile Aspiration™ (APA). An in vitro model with a synthetic clot analog mimicking human thrombus was employed to conduct 300 thrombectomies across five catheters and the two pumps.

Results The ALGO Smart Pump demonstrated superior achievement of complete clot ingestion; CCI occurred in 80.0% of cases with the ALGO Smart pump compared to 38.6% with the Penumbra ENGINE Pump (p<0.001). In cases where CCI was achieved, thrombectomy pump and revascularization times were significantly reduced (p<0.001) and there were fewer distal emboli (p<0.001).

Conclusion Our findings suggest that the ALGO Smart Pump's Adaptive Pulsatile Aspiration (APA™) mode significantly enhances complete clot ingestion (CCI) leading to reduced procedure time and distal emboli. This study supports the adoption of CCI as a valuable metric for assessing thrombectomy efficacy, and emphasizes the need for further clinical validation to confirm these in vitro results.

Disclosures R. Starke: None. J. Thompson: None. M. Silva: None. S. Sanikommu: None. A. Abdelsalam: None. J. Toledo: None. T. Elarjani: None. E. Jaman: None.


LB-009 BALLOON MOUNTED VERSUS SELF-EXPANDABLE STENT IN FAILED NEUROTHROMBECTOMY: A POST HOC ANALYSIS OF THE SAINT STUDY

¹M Mohammaden*, ²P Martins, ²H Aboul-Nour, ³A Al-Bayati, ⁴A Hassan, ⁴W Tekle, ⁵J Fifi, ⁶S Matsoukas, ³O Kuybu, ⁷B Gross, ⁸M Lang, ⁸S Narayanan, ⁹G Cortez, ¹⁰R Hanel, ¹⁰A Aghaebrahim, ¹⁰E Sauvageau, ²M Tarek, ¹¹M Farooqui, ¹²S Ortega-Gutierrez, ¹²C Zevallos, ¹²M Galecio-Castillo, ¹³S Sheth, ¹³M Nahhas, ¹³S Salazar-Marioni, ¹⁴T Nguyen, ¹⁴M Abdalkader, ¹⁴P Klein, ¹⁵M Hafeez, ¹⁵P Kan, ¹⁵O Tanweer, ¹⁶A Khaldi, ¹⁶H Li, ¹⁷M Jumaa, ¹⁷S Zaidi, ¹⁸M Oliver, ¹⁹M Salem, ¹⁹J Burkhardt, ¹⁹B Pukenas, ²⁰R Kumar, ²⁰M Lai, ²⁰J Siegler, ²¹S Peng, ²¹A Alaraj, ⁸R Nogueira, ¹D Haussen. ¹Emory University/Grady Memorial Hospital, Atlanta, GA; ²Emory university, Atlanta, GA; ³Emory university, Pittsburgh, PA; ⁴Emory university, Harlingen, TX; ⁵Emory university, New York, NY; ⁶Mount Saini Hospital, New York, NY; ⁷Neurosurgery, UPMC, Pittsburgh, PA; ⁸UPMC, Pittsburgh, PA; ⁹Emory university, Jacksonville, FL; ¹⁰Baptist Medical Center, Jacksonville, FL; ¹¹University of Iowa Hospitals and Clinics, Iowa City, IA; ¹²University of Iowa Hospitals and Clinics, Iowa, IA; ¹³University of Texas Houston, Houston, TX; ¹⁴Boston University School of Medicine, Boston, MA; ¹⁵Baylor School of Medicine, Houston, TX; ¹⁶WellStar Health System, Marietta, GA; ¹⁷University of Toledo, Toledo, OH; ¹⁸University of Toledo, Toledo, GA; ¹⁹University of Pennsylvania, Philadelphia, PA; ²⁰Cooper University Medical Center, Camden, NJ; ²¹University of Illinois at Chicago, Chicago, IL

10.1136/jnis-2024-SNIS.408

Background Previous studies demonstrated that rescue intracranial stenting in failed thrombectomy has better outcome compared to failed reperfusion. However, there is no data regarding type of stent and its impact on the outcome. We aimed to compare balloon mounted stents (BMS) to self-expandable stents (SES) in terms of clinical and procedural outcomes.

Methods It is a retrospective analysis of prospectively collected database from Stenting and Angioplasty in NeuroThrombectomy (SAINT) study. Patients were included if they had failed thrombectomy and underwent rescue stenting. Patients treated with SES or BMS were compared with inverse probability of treatment weighting. The primary outcome was the final reperfusion as measured by mTICI scale. Secondary outcomes included the shift in the degree of disability as measured by mRS, mRS0-2 and mRS0-3 at 90-days. Safety measures



Abstract LB-009 Figure 1

included rates of symptomatic intracranial hemorrhage, procedural complications and 90-day mortality.

Results A total of 329 patients were included in the analysis. Baseline clinical and procedural characteristics were well balanced among both groups. The BMS (N=125) had higher rates of successful reperfusion (94.4% vs. 86.4%, aOR6.17,95%CI[2.03-18.74],P=0.001) and increased likelihood of higher degree of reperfusion on mTICI scale (acOR2.20,95%CI[1.30-3.70],P=0.003) compared to SES (N=204) (figure 1). However, there was no difference in terms of mRS shift (acOR1.03,95%CI[0.57-1.85],P=0.924), rates of mRS0-2 and mRS0-3 at 90-days. Similarly, safety measures were comparable among both groups.

Conclusions In patients who failed thrombectomy and underwent rescue stenting, our study showed that BMS had higher reperfusion rates compared to SES however, this has not resulted in better clinical outcomes. Further larger controlled studies are warranted.

Disclosures M. Mohammaden: None. P. Martins: None. H. Aboul-Nour: None. A. Al-Bayati: 2; C; Stryker Neurovascular. A. Hassan: 2; C; Medtronic, Microvention, Stryker, Penumbra, Cerenovus, Genentech, GE Healthcare, Scientia, Balt, Viz.ai, Inera therapeutics, Proximie, NovaSignal and Vesalio. W. Tekle: None. J. Fifi: None. S. Matsoukas: None. O. Kuybu: None. B. Gross: 2; C; Medtronic and Microvention. M. Lang: None. S. Narayanan: None. G. Cortez: None. R. Hanel: 2; C; Medtronic, Stryker, Cerenovus, Microvention, Balt, Phenox, Rapid Medical, and Q'Apel. A. Aghaebrahim: 3; C; iSchema View. E. Sauvageau: None. M. Tarek: None. M. Farooqui: None. S. Ortega-Gutierrez: None. C. Zevallos: None. M. Galecio-Castillo: None. S. Sheth: None. M. Nahhas: None. S. Salazar-Marioni: None. T. Nguyen: 1; C; GE Healthcare. TNN: Research support from Medtronic, advisory board Brainomix. 2; C; Medtronic, Stryker Neurovascular. M. Abdalkader: None. P. Klein: None. M. Hafeez: None. P. Kan: None. O. Tanweer: None. A. Khaldi: None. H. Li: None. M.

Jumaa: None. S. Zaidi: None. M. Oliver: None. M. Salem: None. J. Burkhardt: 2; C; Longeviti Neuro Solutions, and Q'Apel Medical. B. Pukenas: None. R. Kumar: None. M. Lai: None. J. Siegler: 2; C; AstraZeneca. S. Peng: None. A. Alaraj: 2; C; Cerenovus. R. Nogueira: 2; C; Stryker Neurovascular, Cerenovus, Medtronic, Phenox, Anaconda, Genentech, Biogen, Prolong Pharmaceuticals, Imperative Care. 4; C; Brainomix, Viz-AI, Corindus Vascular Robotics, Vesalio, Ceretrieve, Astrocyte and Cerebrotech. D. Haussen: 2; C; Stryker and Vesalio. 4; C; Viz.AI.

LB-010 RESCUE STENTING IN FAILED THROMBECTOMY

¹F Qoorchi Moheb Seraj, ²S Najafi, ³L Afshar Hezarkhani, ⁴M Mohammad yari, ⁵F Ebrahimnia, ¹P Sasannejad, ⁶A Mowla, ⁷H Baharvahdat. ¹Neurovascular Section, Neurosurgical Department, Mashhad University of Medical Sciences, Mashhad, Iran, Islamic Republic of; ²Neurovascular Section, Neurosurgical Department, Mazandaran University of Medical Sciences, Sari, Iran, Islamic Republic of; ³Neurovascular Section, Kermanshah University of Medical Sciences, Kermanshah, Iran, Islamic Republic of; ⁴Neurovascular Section, Neurosurgical Department, Kermanshah University of Medical Sciences, Kermanshah, Iran, Islamic Republic of; ⁵Neurovascular Section, Neurosurgical Department, Iran University of Medical Sciences, Tehran, Iran, Islamic Republic of; ⁶Neurosurgery Department, Keck school of Medicine, Los Angeles, CA; ⁷Interventional Neuroradiology, Hopital Fondation Adolphe de Rothschild, Paris, France

10.1136/jnis-2024-SNIS.409

Background Mechanical thrombectomy (MT) is a primary endovascular modality for acute intracranial large vessel occlusion. However, in the failed occasion further treatment, such as rescue stenting, is occasionally. We aimed to investigate the efficacy and safety of rescue stenting in first-line MT failure and to identify the clinical factors affecting its clinical outcome.

Methods In this multicenter study, the authors review the medical records of patients who were treated with mechanical